glp 1 agonist in pregnancy Prenatal exposure to GLP-1 receptor agonists and other second-line antidiabetics may not pose greater risk to infants than insulin Maternal GLP-1 receptor activation inhibits

In relative terms, that means people taking the injected drugs were more than three times more likely to develop stomach paralysis compared with those taking Contrave

Weight reduction Compared with placebo, use of dulaglutide 1.5 mg once weekly led to a 1.5 kg (95% CI 1.3 to 1.7 kg) weight reduction over five years

Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node

Figure 31: Photograph of Professor Bernard Thorens, credit Center for Integrative Genomics, University of Lausanne

Code availability The analytic code is available at Change history 31 January 2025 A Correction to this paper has been published: References Pfeffer, M

Additionally, monoclonal antibodies targeting substances like fentanyl are being developed to block their effects before they reach the brain, potentially reducing overdose risks